Entries by admin

Event: Conference Call – Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta

June 26, 2017 Time of Event: 1:30 p.m. Pacific standard time / 4:30 p.m. Eastern Time Conference Call Details: Toll-free from the US: (855) 433-0927 internationally: (484) 756-4262 conference ID: 45257837. Webcast Details:  The call will also be webcast live at http://edge.media-server.com/m/p/izdfc9hq. A replay will also be available at the link above for 30 days. For […]

Kindred Biosciences Announces Acquisition of Kansas Manufacturing Plant and Execution of Commercial Manufacturing Agreement for Zimeta

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Monday, June 26, 2017 San Francisco, CA (June 26, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has acquired a manufacturing facility in […]

Kindred Biosciences Added to the Russell 2000 Index

San Francisco, June 15, 2017 /PRNewswire/ — Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will join the US small-cap Russell 2000® Index, effective after the US market closes on June 23, according to a preliminary list of additions and the market capitalization […]

Kindred Biosciences to Present at 7th Annual LD Micro Invitational

San Francisco, CA (May 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that Denise Bevers, Co-Founder and COO, will be presenting and hosting one-on-one investor meetings at the 7th Annual LD Micro Invitational in Los Angeles, CA on Tuesday, June 6, 2017 at […]

Kindred Biosciences Announces First Quarter 2017 Financial Results

San Francisco, CA (May 3, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2017 and provided updates on its programs. “The first quarter of 2017 has been extremely successful for KindredBio. We continue to […]

Kindred Biosciences Announces Initiation of Enrollment in Pivotal Effectiveness Trial of Zimeta Oral for the Control of Fever in Horses

San Francisco, CA (May 1, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that the first patient has been enrolled in the pivotal effectiveness trial evaluating its novel, oral formulation of Zimeta™ (dipyrone oral gel) for the control of fever in horses. “We […]

Kindred Biosciences to Announce First Quarter 2017 Financial Results

Kindred Biosciences to Announce First Quarter 2017 Financial Results Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, May 3, 2017 San Francisco, CA (April 24, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today […]